Back to top
more

Salarius Pharmaceuticals (SLRX)

(Delayed Data from NSDQ)

$0.50 USD

0.50
4,071

0.00 (-0.78%)

Updated Apr 26, 2024 03:58 PM ET

After-Market: $0.48 -0.02 (-3.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SLRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Salarius Pharmaceuticals, Inc. [SLRX]

Reports for Purchase

Showing records 1 - 20 ( 44 total )

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/05/2024

Company Report

Pages: 5

Investment Highlights

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/13/2023

Company Report

Pages: 11

Encouraging Additional Early-Stage Clinical Findings and FDA Type B Meeting Provide Clarity Around Trial Advancements

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/09/2023

Company Report

Pages: 10

Encouraging Additional Early-Stage Clinical Findings and FDA Type B Meeting Provide Clarity Around Trial Advancements

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/15/2023

Company Report

Pages: 10

Q2 2023 Financial Result Update, Program Advancements and Strategic Shifts

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

07/14/2023

Company Report

Pages: 10

Continued Progress Highlighted by Significant Milestone

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

06/14/2023

Company Report

Pages: 10

Promising Preclinical Data for SalariusPharmaceuticals'' Novel Molecular Glue, SP-3164, Presented at EHA 2023

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/15/2023

Company Report

Pages: 10

Q1 2023 Financial and Operational Updates

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/10/2023

Company Report

Pages: 10

FDA Removes Seclidemstat Partial Clinical Hold and Company Achieves Further Progress Across Clinical Pipeline

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

04/24/2023

Company Report

Pages: 10

Encouraging Pre-clinical Trial Results Demonstrating SP-3164’s Compelling Anti-Tumor Activity

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/29/2023

Company Report

Pages: 10

Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/09/2023

Company Report

Pages: 10

Presentation of In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/16/2023

Company Report

Pages: 10

Encouraging SP-3164 Preclinical Trial Data Presentation and Expansion of Intellectual Property Protection

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/02/2022

Company Report

Pages: 5

Encouraging Interim Results from Phase 1/2 Trial of Seclidemstat

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/14/2022

Company Report

Pages: 10

3Q FY 2022 Financial Result Update

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/07/2022

Company Report

Pages: 10

Showcasing Novel Compound with Potential for Improved Anti-Cancer Activity

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/20/2022

Company Report

Pages: 8

Pause in New Patient Enrollment in Seclidemstat Trial.

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/11/2022

Company Report

Pages: 8

Investment Highlights

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/18/2022

Company Report

Pages: 5

Significant Development of Existing Programs with Data Updates Anticipated in 2022

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/18/2022

Company Report

Pages: 3

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/17/2022

Company Report

Pages: 5

Expanding into Large Targeted

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 5.00

Research Provided by a Third Party